Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases.
Abstract | BACKGROUND: METHODS: RESULTS: By ELISA, the receiver operating characteristics analysis yielded an area under the curve of 0.98 (95% CI: 0.9638-1.005), allowing to set the cut-off at 0.32 OD at a calculated specificity of 98% and a sensitivity of 94%. Running the optimized test showed that serum IgG autoantibodies from 47 EBA (94%; 95% CI: 87.41%-100%), 2 CD (4%; 95% CI: 0%-9.43%), 8 UC (16%; 95% CI: 5.8%-26%), 2 BP (2.63%; 95% CI: 0%-6.23%), and 4 PV (9.52%; 95% CI: 0%-18.4%) patients as well as from 4 (1.63%; 95% CI: 0%-3.21%) healthy donors reacted with the chimeric protein. Further analysis revealed that in 34%, 37%, 16% and 100% of sera autoantibodies of IgG1, IgG2, IgG3, and IgG4 isotype, respectively, recognized the recombinant autoantigen. CONCLUSIONS:
|
Authors | Emilia Licarete, Susanne Ganz, Martin J Recknagel, Giovanni Di Zenzo, Takashi Hashimoto, Michael Hertl, Giovanna Zambruno, Gheorghe Hundorfean, Jonas Mudter, Markus F Neurath, Leena Bruckner-Tuderman, Cassian Sitaru |
Journal | BMC immunology
(BMC Immunol)
Vol. 13
Pg. 16
(Apr 04 2012)
ISSN: 1471-2172 [Electronic] England |
PMID | 22471736
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Autoantibodies
- Collagen Type VII
- Epitopes
- Immunoglobulin G
- Inflammation Mediators
- Recombinant Fusion Proteins
- C-Reactive Protein
|
Topics |
- Autoantibodies
(blood)
- Autoimmune Diseases
(blood, immunology)
- C-Reactive Protein
(metabolism)
- Cells, Cultured
- Collagen Type VII
(genetics, immunology)
- Enzyme-Linked Immunosorbent Assay
- Epitope Mapping
- Epitopes
(genetics, immunology)
- Humans
- Immunoglobulin G
(blood)
- Inflammation
(blood, immunology)
- Inflammation Mediators
(metabolism)
- Protein Engineering
- Protein Structure, Tertiary
(genetics)
- Recombinant Fusion Proteins
(genetics, immunology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|